Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Astellas Paying $5.9bn For Iveric To Boost Ophthalmology Presence

Eyes Post-Xtandi Revenues

Executive Summary

Astellas set to acquire private US firm to add to its strategic capabilities in ophthalmology focus area, along with another revenue pillar as it prepares for Xtandi expiry. 

You may also be interested in...



Japan Q3 Roundup: Daiichi Emerges As Growth Leader While Others Balance Ups And Downs

The success of Enhertu led Daiichi Sankyo to raise its annual forecast for the fiscal year ending 31 March, while Eisai is readying for Leqembi’s steady US growth. Meanwhile, Astellas, Chugai and Shionogi balanced growth for some products with declines for others.

J.P. Morgan Day Two: Novo Talks Obesity Outlook, Lilly Looks To Alzheimer's, New Fields

Daily notebook from the J.P. Morgan Healthcare Conference: Novo makes its debut appearance and welcomes newcomers to the obesity market; Novartis weighs its options in obesity; Lilly expects donanemab to launch into a primed Alzheimer's market – and it continues to look for more large-market opportunities; and Apellis sees strong 2023 Syfovre sales.

Astellas’ Izervay Joins Geographic Atrophy Market, Intensifying Competition

The C5 inhibitor, recently acquired by Astellas, will be commercially available in two to four weeks and will compete against Apellis Pharma’s Syfovre.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel